Neuland Laboratories Intrinsic Value
Neuland Laboratories (NEULANDLAB) median intrinsic value is ₹7418.40 from 10 valuation models (range ₹3709–₹14587), vs current price ₹18546.00 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read NEULANDLAB dividend growth for the complete payout history and dividend yield track record.
NEULANDLAB Valuation Methods Summary — DCF, Graham Number & P/E
Neuland Laboratories intrinsic value across 10 models vs current price ₹18546.00 — upside/downside and value range per method. For current market price and key ratios, visit Neuland Laboratories share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹14586.88 | ₹11669.50 - ₹17504.26 | -21.3% | EPS: ₹663.04, Sector P/E: 22x |
| Book Value Method | asset | ₹3709.20 | ₹3338.28 - ₹4080.12 | -80.0% | Book Value/Share: ₹1442.31, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹5563.80 | ₹5007.42 - ₹6120.18 | -70.0% | Revenue/Share: ₹2427.69, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹9846.15 | ₹8861.53 - ₹10830.77 | -46.9% | EBITDA: ₹1280.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹7418.40 | ₹5934.72 - ₹8902.08 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹5563.80 | ₹5007.42 - ₹6120.18 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹10243.97 | ₹9219.57 - ₹11268.37 | -44.8% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹10486.15 | ₹9437.53 - ₹11534.77 | -43.5% | ROE: 45.4%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹5563.80 | ₹5007.42 - ₹6120.18 | -70.0% | EPS: ₹663.04, BVPS: ₹1442.31 |
| Dividend Yield Method | dividend | ₹5563.80 | ₹5007.42 - ₹6120.18 | -70.0% | DPS: ₹34.00, Target Yield: 2.5% |
NEULANDLAB Intrinsic Value vs Market Price — All Valuation Models
Neuland Laboratories fair value range ₹3709–₹14587 vs current market price ₹18546.00 across 10 valuation models. Analyse Neuland Laboratories ownership pattern to track promoter, FII and institutional holdings.
NEULANDLAB Intrinsic Value Analysis — Undervalued or Overvalued?
Neuland Laboratories median intrinsic value ₹7418.40, current price ₹18546.00 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of NEULANDLAB?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Neuland Laboratories (NEULANDLAB) is ₹7418.40 (median value). With the current market price of ₹18546.00, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹3709.20 to ₹14586.88, indicating ₹3709.20 - ₹14586.88.
Is NEULANDLAB undervalued or overvalued?
Based on our multi-method analysis, Neuland Laboratories (NEULANDLAB) appears to be trading above calculated value by approximately 60.0%.
NEULANDLAB Financial Health — Key Ratios vs Industry Benchmarks
Neuland Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.29 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 45.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 40.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.08x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
NEULANDLAB Cash Flow Quality — Operating & Free Cash Flow
Neuland Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹347 Cr | ₹136 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹317 Cr | ₹168 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹261 Cr | ₹186 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹237 Cr | ₹207 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹60 Cr | ₹13 Cr | Positive Free Cash Flow | 7/10 |